Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

A Challenge for Alcon R&D - Integration with Novartis

December 5, 2008

Analysis of:Novartis and Nestlé in a Deal for Alcon | select.nytimes.com

My viewpoint of the staged acquisition of Alcon by Novartis focuses on the implication to Alcon R&D. At least two key shifts will occur (and in fact have already started)... 1. R&D activities will become much more collaborative. In the past, Alcon has developed many of their key technologies in house (witness the acrylic monomer for Acrysof). Now, I would expect to see key developments done in collaborations with universities and other technology based companies. This may result in lower development costs for Alcon, but will likely give competitors and the public an earlier view into their pipeline. 2. R&D senior management will include those with medical backgrounds. This has already begun (note Alcon's recent appointment of Sabri Markabi, MD from Novartis as SVP R&D). This will of course ensure a tight bond between management and clinician/surgeon, but may challenge the new management to understand the complexities inherient in the introduction of new technologies.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS